sever
acut
respiratori
syndrom
sar
recent
emerg
infecti
diseas
character
persist
fever
respiratori
symptom
lung
consolid
lymphopenia
respiratori
failur
lifethreaten
case
wateri
diarrhoea
also
manifest
case
found
lymphopenia
deplet
lymphocyt
could
associ
diseas
activ
advers
outcom
sar
sarsrel
death
result
mainli
pulmonari
complic
includ
progress
respiratori
failur
due
alveolar
damag
acut
respiratori
distress
syndrom
ard
caus
agent
sar
identifi
new
coronaviru
sarscov
genom
sequenc
moder
relat
known
coronavirus
rapid
diagnost
test
use
molecular
techniqu
detect
sarscov
rna
develop
recent
administr
antivir
drug
ribarivin
togeth
system
corticosteroid
result
allevi
inflamm
reduct
organ
dysfunct
improv
surviv
major
sar
patient
although
control
clinic
trial
requir
confirm
regimen
genuin
efficaci
shown
overproduct
specif
inflammatori
cytokin
tumour
necrosi
factor
tnf
interleukin
il
polymorphonuclear
neutrophil
pmn
cc
chemokin
hallmark
viral
infect
probabl
activ
transcript
factor
nuclear
factor
nf
activ
protein
ap
activ
exampl
avian
flu
influenza
virus
potent
induc
proinflammatori
cytokin
macrophag
swine
pneumonia
product
found
correl
posit
diseas
sever
therefor
sar
sequala
transendotheli
migrat
pmn
lung
tissu
multipl
organ
dysfunct
ard
postul
associ
cytokin
chemokin
dysregul
attempt
studi
possibl
sarscovinduc
cytokin
chemokin
dysregul
identifi
marker
diseas
sever
explor
feasibl
design
effect
treatment
strategi
anticytokin
therapi
prospect
investig
panel
circul
helper
th
cell
cytokin
inflammatori
cytokin
chemokin
patient
sar
studi
includ
consecut
adult
patient
diagnos
sar
admit
princ
wale
hospit
hong
kong
treatment
march
april
accord
world
health
organ
case
definit
fever
temperatur
chest
radiograph
comput
tomograph
imag
thorax
show
evid
new
consolid
without
respiratori
symptom
eg
cough
short
breath
histori
close
contact
person
sar
diagnos
diagnosi
sar
confirm
indirect
immunofluoresc
assay
fetal
rhesu
kidney
cell
infect
coronaviru
fix
aceton
detect
serolog
respons
sarscov
posit
viral
cultur
protocol
approv
clinic
research
ethic
committe
chines
univers
hong
kong
inform
consent
obtain
particip
edta
blood
sampl
collect
sar
patient
daili
maximum
consecut
day
immers
ice
transport
immedi
laboratori
process
plasma
separ
centrifug
g
min
store
aliquot
analysi
commonli
use
procedur
enzymelink
immunosorb
assay
elisa
may
gener
infecti
droplet
aerosol
helper
th
cytokin
inflammatori
cytokin
chemokin
plasma
measur
serial
cytometr
bead
array
cba
use
fourcolour
facscalibur
flow
cytomet
becton
dickinson
ca
usa
locat
biosafeti
level
ii
laboratori
cba
five
six
bead
popul
distinct
fluoresc
intens
coat
captur
antibodi
specif
differ
cytokin
chemokin
bead
popul
could
resolv
fluoresc
channel
flow
cytomet
bead
incub
plasma
differ
cytokin
chemokin
sampl
captur
correspond
bead
cytokinechemokin
captur
bead
mix
phycoerythrinconjug
detect
antibodi
form
sandwich
complex
follow
incub
wash
acquisit
fluoresc
data
result
gener
graphic
format
use
bd
cba
softwar
concentr
cytokin
inflammatori
cytokin
chemokin
regul
upon
activ
normal
cellexpress
secret
rant
monocyt
chemoattract
monokin
induc
mig
measur
use
human
cytokin
inflammatori
cytokin
chemokin
cba
kit
bd
pharmingen
ca
usa
respect
assay
sensit
eight
cytokin
five
chemokin
ngl
respect
coeffici
variat
cytokin
chemokin
assay
less
respect
normal
rang
deriv
measur
healthi
subject
plasma
cytokin
chemokin
concentr
gaussian
distribut
rank
sum
test
use
assess
differ
result
express
median
interquartil
rang
analys
perform
use
statist
packag
social
scienc
spss
softwar
window
version
spss
inc
il
usa
probabl
p
consid
significantli
differ
characterist
sar
patient
summar
tabl
coincident
except
one
femal
patient
although
femaletomal
ratio
sar
patient
outbreak
hong
kong
well
patient
treat
princ
wale
hospit
none
sar
patient
recruit
studi
die
requir
admiss
intens
care
unit
icu
initi
treatment
includ
antibiot
cefotaxim
clarithromycin
levofloxacin
cover
common
pathogen
caus
communityacquir
pneumonia
oseltamivir
tamiflu
also
given
initi
treat
possibl
influenza
infect
fever
persist
h
leukopenia
thrombocytopenia
develop
oral
ribavirin
mgkgday
oral
prednisolon
mgkgday
start
combin
regimen
day
diseas
fever
onset
patient
respond
clinic
standard
empir
treatment
includ
persist
fever
increas
short
breath
worsen
lung
opac
involv
lung
field
chest
radiograph
deterior
oxygen
satur
puls
oximetri
given
intraven
ribavirin
mg
everi
h
addit
one
three
puls
g
methylprednisolon
sodium
succin
methylprednisolon
daili
longitudin
trend
plasma
cytokin
inflammatori
cytokin
sar
patient
illustr
fig
cytokin
inflammatori
cytokin
concentr
significantli
elev
normal
rang
respect
within
first
day
diseas
onset
p
contrast
signific
increas
proinflammatori
cytokin
sar
patient
antiinflammatori
cytokin
found
increas
patient
overal
signific
plasma
concentr
cytokin
cytokin
patient
low
within
respect
normal
rang
time
point
data
shown
shown
fig
plasma
pmn
cc
chemokin
monocyt
cc
chemokin
cxc
chemokin
concentr
elev
respect
within
first
day
diseas
onset
p
overal
plasma
concentr
cell
chemoattract
name
cxc
chemokin
mig
cc
chemokin
rant
significantli
elev
among
sar
patient
cohort
sever
diseas
activ
includ
persist
fever
worsen
lung
opac
addit
given
intraven
puls
methylprednisolon
seven
patient
milder
diseas
sever
treat
puls
steroid
figur
show
plasma
former
group
patient
higher
median
concentr
latter
particularli
day
diseas
onset
follow
recoveri
cytokin
chemokin
level
decreas
progress
normal
valu
week
diseas
onset
group
patient
summar
tabl
plasma
chemokin
significantli
reduc
respect
normal
rang
day
corticosteroid
treatment
compar
elev
pretreat
level
p
posttreat
concentr
also
significantli
lower
day
treatment
p
measur
cytokin
chemokin
rant
mig
show
signific
differ
corticosteroid
treatment
studi
design
investig
prospect
longitudin
plasma
cytokin
chemokin
profil
adult
patient
sar
progress
potenti
lethal
diseas
may
repres
three
phase
acut
viral
multipl
hyperact
immun
respons
recoveri
pulmonari
destruct
death
accordingli
worthwhil
investig
cytokin
chemokin
induct
may
caus
consequ
immun
hyperact
sar
observ
least
week
diseas
onset
sar
patient
exhibit
signific
increas
typic
antivir
cytokin
array
proinflammatori
cytokin
togeth
moder
increas
antiinflammatori
manifest
patient
act
earli
respons
cytokin
viral
infect
caus
human
immunodefici
viru
mediat
inflammatori
respons
synthesi
acut
phase
protein
releas
may
play
proinflammatori
role
pulmonari
inflamm
cytokin
antiinflammatori
cytokin
suppress
secret
proinflammatori
cytokin
therefor
elev
patient
week
diseas
onset
follow
elev
inflammatori
cytokin
also
known
natur
killer
nk
cell
stimulatori
factor
cytotox
lymphocyt
matur
factor
pleiotrop
proinflammatori
cytokin
produc
primarili
antigenpres
cell
monocyt
macrophag
dendrit
cell
b
cell
pmn
induc
product
cytokin
suppress
pathway
multipl
effect
lymphocyt
nk
cell
includ
abil
stimul
cytotox
prolifer
cytokin
product
develop
subset
therefor
observ
earli
elev
inflammatori
cytokin
could
caus
sarscovinduc
activ
cell
nk
cell
releas
chemokin
result
pulmonari
inflamm
previou
studi
suggest
infiltr
proinflammatori
pmn
involv
pathogenesi
acut
lung
injuri
pmn
abund
airspac
ard
patient
infect
secretori
product
myeloperoxidas
elastas
bronchoalveolar
lavag
bal
fluid
caus
acut
lung
injuri
pmn
shown
elev
blood
alveolar
space
exhibit
posit
correl
number
pmn
bal
fluid
patient
pneumonia
ard
sarscovinfect
patient
also
show
elev
plasma
soon
diseas
onset
declin
day
corticosteroid
treatment
former
clinic
studi
sar
patient
develop
neutrophilia
high
neutrophil
count
associ
icu
admiss
mortal
pneumonia
therefor
pmninduc
acut
pneumon
crucial
pathogenesi
ard
pulmonari
destruct
sar
patient
apart
also
observ
elev
monocytemacrophag
soon
onset
sar
follow
declin
corticosteroid
treatment
concentr
shown
increas
bal
fluid
patient
persist
ard
correl
posit
predomin
alveolar
macrophag
also
found
postmortem
examin
sar
patient
specif
chemoattract
cell
activ
cellmedi
immun
respons
express
upregul
cytokin
acut
lung
inflamm
consist
result
show
circul
increas
sar
patient
observ
low
normal
cytokin
sar
patient
also
similar
find
previou
studi
viral
pneumonia
suggest
sarscov
enhanc
pathway
subsequ
humor
immu
respons
imbal
cytokin
profil
confirm
sarscovinduc
predomin
contrast
infect
plasma
elev
patient
find
therefor
support
therapeut
use
monoclon
antibodi
sar
howev
must
caution
concentr
pulmonari
inflammatori
site
investig
previou
studi
implic
inflammatori
acutephas
cytokin
endogen
pyrogen
induc
fever
therefor
elev
might
account
fever
onset
found
high
plasma
concentr
first
week
diseas
moreov
cell
chemokin
mig
rant
also
show
significantli
elev
therefor
recruit
activ
cell
pulmonari
tissu
studi
perform
chemokin
assay
differenti
cell
count
bal
fluid
although
difficult
high
risk
infect
summari
postul
elev
plasma
chemokin
cytokin
inflammatori
cytokin
induc
hyperinn
inflammatori
respons
due
sarscov
invas
respiratori
tract
lead
recruit
accumul
alveolar
macrophag
pmn
well
activ
cellmedi
immun
stimul
nk
cytotox
lymphocyt
ctl
treatment
immunosuppress
corticosteroid
significantli
suppress
elev
chemokin
subsequ
allevi
chemokineassoci
pulmonari
inflamm
sar
inde
reduct
correl
improv
gener
clinic
condit
pulmonari
function
radiolog
appear
sar
patient
present
studi
addit
also
observ
higher
diseas
sever
associ
elev
plasma
concentr
fig
postul
addit
puls
steroid
severediseas
group
control
rapidli
deterior
clinic
condit
basic
attenu
otherwis
overexagger
immunolog
respons
potenti
much
high
median
concentr
plasma
cytokin
chemokin
support
cytokin
chemokin
play
import
role
immunopatholog
mechan
sar
initi
studi
compar
plasma
cytokin
chemokin
sar
patient
without
corticosteroid
treatment
elev
plasma
cytokin
chemokin
also
shed
light
possibl
use
prognost
indic
diseas
sever
sar
exampl
presenc
high
complex
bal
fluid
shown
import
prognost
indic
ard
although
studi
provid
understand
immunolog
mechan
inflamm
sar
therapeut
effect
corticosteroid
mani
investig
requir
explor
detail
pathophysiolog
novel
emerg
diseas
global
impact
order
correl
cytokin
releas
diseas
sever
vitro
mechanist
studi
cytokin
induct
use
sarscov
immun
cell
cultur
eventu
measur
cytokin
chemokin
concentr
local
inflammatori
site
contempl
chemokin
epitheli
neutrophilactiv
peptid
ena
neutrophil
chemoattract
macrophag
inflammatori
alpha
monocyt
chemoattract
measur
recent
transform
growth
factor
tgf
shown
activ
earli
acut
lung
injuri
potenti
contribut
develop
pulmonari
oedema
therefor
role
sar
also
requir
investig
given
promin
role
cytokin
chemokin
pathogenesi
sar
anticytokinechemokin
immunotherapi
use
anticytokinechemokin
antibodi
eg
cytokinechemokin
antagonist
may
repres
novel
approach
treatment
hyperact
inflamm
sar
